The CEO's open-market purchase of $391K, his first disclosed buy in the cluster window, is a strong signal of confidence following the Q3 beat and Heron deal announcement. Monitor for any additional insider purchases or 13D filings that could indicate further conviction. The cluster size (0.13% of market cap) is modest but meaningful given the CEO's participation and the absence of a 10b5-1 plan.
Drugs in focus
CRMD drug pipeline →rezafungin
▲ Bullish Named in this insider cluster- Impact
- Phase
- Approved
- Time to market
- Already marketed (approved March 2023). The supplemental indication for prophylaxis has a PDUFA target in Q1 2027, with a promotional launch targeted for H2 2027 if approved.
- Next catalyst
- NDA filing · 2026
What to watchWatch for the specific PDUFA date announcement (Q1 2027) for the REZZAYO prophylaxis sNDA, which is the next major binary catalyst. The stock trades at ~$7.85 with ~$15.33 analyst target (95% upside) but carries ~20% short interest, suggesting a potential squeeze setup if the sNDA is approved. Monitor Q3 earnings on Nov 11, 2026 for REZZAYO revenue trajectory in the currently approved indications.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 19 $5.08entry
- T+1 · 2d ago +3.74%α +7.38% · $5.27
- T+5 · in 5d Pending
- T+20 · in 26d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at CorMedix, including CEO Joseph Todisco and Director Myron Kaplan, made open-market purchases totaling $513K over a 7-day window. The CEO's $391K buy and the Director's $122K buy follow the company's Q3 2026 earnings release (revenue beat, narrowed EBITDA guidance) and the announced Heron Therapeutics asset acquisition, signaling insider confidence in the post-earnings outlook and growth strategy.
Key Financial Metrics
Key Facts
- CEO Joseph Todisco purchased 80,000 shares at $4.89 for $391,200 on 2026-11-13 (open-market, no 10b5-1 plan)
- Director Myron Kaplan purchased 25,000 shares at $4.88 for $122,000 on 2026-11-16 (open-market, no 10b5-1 plan)
- Total insider purchases of $513,200 represent 0.13% of the $383M market cap
- Purchases occurred 1-4 days after Q3 2026 earnings (Nov 12) which beat revenue consensus ($54.5M vs $51.2M) and narrowed adjusted EBITDA guidance
- Company recently announced acquisition of Heron Therapeutics assets, expected to close Q1 2027 and be immediately accretive
Financial Impact
Total insider purchases of $513K, representing 0.13% of market cap
Risk Factors
- Insider purchases are modest relative to market cap (0.13%) and may not reflect broad insider sentiment
- Q3 2026 revenue declined YoY from $104.3M to $54.5M due to post-TDAPA pricing headwinds for DefenCath
- Company suspended 2027 DefenCath revenue guidance due to CMS reimbursement uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CRMD-1795040520059 |
Track record
24 reports on CRMD
9 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 11 of 13 went positive at some point.
Filters
- Nov 20, 20261d ago Insider Cluster Bullish 5/10 Entry $5.28 Now $5.27 −0.09% settles Nov 30
- Nov 18, 20263d ago Insider Cluster Bullish 4/10 Viewing Entry $5.08 Now $5.27 +3.74% settles Nov 27
- Nov 13, 20268d ago DEFA14A / 8-K Bearish 6/10 Entry $4.82 Now $5.27 −9.34% settles Nov 23
- Nov 12, 202610d ago Press Release Bearish 5/10 Entry $4.84 to $5.08 Now $5.27 −8.88% ▼ −4.96% −10.41% vs SPY
- Nov 10, 202611d ago DEFA14A Neutral 6/10 Entry $5.30 to $4.50 Now $5.27 −0.57% ▼ −15.09% −11.20% vs SPY
- Nov 10, 202611d ago 8-K Bullish 7/10 Entry $5.30 to $4.50 Now $5.27 −0.57% ▼ −15.09% −11.20% vs SPY
- Nov 9, 202612d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $5.27 −3.66% ▼ −11.88% −10.19% vs SPY
- Nov 9, 202612d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $5.27 −3.66% ▼ −11.88% −10.19% vs SPY
- Nov 2, 202620d ago 8-K Neutral 5/10 No price data
- Nov 2, 202620d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $5.27 −2.23% ▲ +1.48% +1.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers